all objective response rate was the primary study end point.
The researchers found that 86%, 57%, and 29% of patients achieved an objective response, a complete remission (CR), and a partial remission, respectively. The median duration was 12.6 months for overall response and 13.2 months for CR. The most common Grade 3 or 4 adverse events were neutropenia, thrombocytopenia, and peripheral sensory neuropathy.
"Brentuximab vedotin induced objective responses in the majority of patients and CRs in more than half of patients with recurrent systemic ALCL," the authors write. "Targeted therapy with this CD30-directed antibody-drug conjugate may be an effective treatment for relapsed or refractory systemic ALCL and warrants further studies in front-line therapy."
Several authors disclosed financial ties to Seattle Genetics, which funded the study and manufactures brentuximab vedotin.
|
